<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322618</url>
  </required_header>
  <id_info>
    <org_study_id>2017-33</org_study_id>
    <secondary_id>2017-A01705-48</secondary_id>
    <nct_id>NCT03322618</nct_id>
  </id_info>
  <brief_title>Evaluation of the Expression and Functions of the KIR3DL2 Receptor and the Anti-inflammatory Activity of IPH4102 in Blood Samples</brief_title>
  <acronym>KIR3DL2</acronym>
  <official_title>Evaluation of the Expression and Functions of the KIR3DL2 Receptor and the Anti-inflammatory Activity of IPH4102 (Monoclonal Antibody IPH4102 Targeting KIR3DL2) in Blood Samples Taken From Patients With Axial Spondyloarthritis and Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the main objectives are

        1. to study the pathophysiological role of KIR3DL2 in axSpA and its relationship with Th17
           immunity in HLA-B27 + and HLA-B27- patients and

        2. to assess the effect on the pro-inflammatory immune response of a cytotoxic monoclonal
           antibody IPH4102 (anti-KIR3DL2) in these patients.

      The study will be carried out on blood samples from 24 patients with axSpA, 12 HLA-B27 + and
      12 HLA-B27-, without any drug injection nor direct therapeutic benefit for the participating
      patients and 12 healthy controls.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the present various immunizing populations in patients' blood SPA HLA-B27 + and HLA-B27-(Lymphocytes T CD4 (Th1 Th2, Th17, Tregs), lymphocytes T CD8, cells NK, lymphocytes B, monocytes)</measure>
    <time_frame>12 MONTHS</time_frame>
    <description>by flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression of the receivers involved in SPA on lymphocytes T CD4 in percentage of cells T CD4 expressing this markers</measure>
    <time_frame>12 MONTHS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of cytokines</measure>
    <time_frame>12 MONTHS</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Axial Spondyloarthritis (axSpA)</condition>
  <condition>Ankylosing Spondylitis (AS)</condition>
  <arm_group>
    <arm_group_label>SpA HLA-B27 +,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SpA HLA-B27-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy subject</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>7 tubes of 6 ml (42 ml of blood )</description>
    <arm_group_label>SpA HLA-B27 +,</arm_group_label>
    <arm_group_label>SpA HLA-B27-</arm_group_label>
    <arm_group_label>healthy subject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent of the patient signed before any procedure planned to the protocol

          -  SPA axial according to the criteria of the ASAS (international Assessment of
             SpondyloArthritis Society)

          -  Known Status HLA B27

          -  Disease activates with a score of BASDAI = 4/10. The BASDAI (Bath Ankylosing
             Spondylitis Disease Activity Score) is a composite indication(index), validated, used
             in the therapeutic essays and in current practice for the evaluation of the activity
             of the SPA.

          -  Naive Patients of thorough treatment

          -  Patients of 18 and more years old

        Exclusion Criteria:

          -  Minors

          -  Pregnant or breast-feeding Women

          -  Adults under guardianship

          -  People staying in a sanitary or social establishment

          -  People in emergency situation

          -  Not profitable People of a national insurance scheme

          -  Private persons of freedom

          -  Treatment by corticoids during the last 30 days before the inclusion

          -  Treatment by anti-TNF or quite different biomedicine

          -  Treatment by sulfasalazine

          -  Reached concomitant by another active chronic inflammatory disease

          -  Infection chronicles by VHB, VHC or HIV

          -  Patients included in another study of clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>thao pham</last_name>
    <phone>04 91 74 63 21</phone>
    <email>thao.pham@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JEAN OLIVIER ARNAUD</last_name>
      <phone>0491382747</phone>
      <email>drci@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Thao PHAM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

